Home > Dermatology > AAD 2022 > Posters > Upadacitinib: Fast and more pronounced skin improvement in AD patients

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By
Prof. Jonathan Silverberg, George Washington University School of Medicine, USA
Presented by
Jonathan Silverberg
Conference
AAD 2022
Trial
Phase 3, Heads Up
A novel analysis of the Heads Up trial revealed that a larger proportion of adult patients with moderate-to-severe atopic dermatitis (AD) achieved incrementally greater levels of skin improvement with the Janus kinase (JAK) inhibitor upadacitinib compared with patients treated with dupilumab. This effect might lead to a better quality of life in these patients. Previously, the superior efficacy of the selective JAK inhibitor upadacitinib compared with dupilumab for the treatment of moderate-to-severe AD was demonstrated in the phase 3b, randomised Heads Up study (NCT03738397) [1]. The primary study endpoint was the proportion of patients that achieved an improvement in the Eczema Area and Severity Index (EASI) by 75% from baseline at week 16. Participants were randomised 1:1 to receive either oral upadacitinib 30 mg once daily (with a placebo prefilled syringe ever...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on